Key genetic code change drives common lung cancer type

byNYU Langone HealthGraphical abstract. Credit:Cancer Cell(2022). DOI: 10.1016/j.ccell.2022.11.015A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has i

Updated on: December 22,2023 9

Key genetic code change drives common lung cancer type

byNYU Langone HealthGraphical abstract. Credit:Cancer Cell(2022). DOI: 10.1016/j.ccell.2022.11.015A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has i

Updated on:December 22,2023 9

Pioneering mRNA-4157 Cancer Vaccines: Personalized Immunotherapy for Targeted Treatment

Updated on: June 13,2024 1

Pioneering mRNA-4157 Cancer Vaccines: Personalized Immunotherapy for Targeted Treatment

Updated on:June 13,2024 1

Novel risk score for cardiovascular complications after bone marrow transplant

by Noah Fromson,University of Michigan3D Model of the heart by Dr. Matthew Bramlet. Credit: NIHFor thousands of Americans each year, a bone marrow transplant has the potential to cure diseases s

Updated on: March 20,2024 12

Novel risk score for cardiovascular complications after bone marrow transplant

by Noah Fromson,University of Michigan3D Model of the heart by Dr. Matthew Bramlet. Credit: NIHFor thousands of Americans each year, a bone marrow transplant has the potential to cure diseases s

Updated on:March 20,2024 12

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on: January 04,2024 9

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on:January 04,2024 9

Study finds African Americans with cancer at higher risk for blood clots

byBoston University School of MedicineCredit: CC0 Public DomainAfrican-Americans are at higher risk for cancer-associated venous thromboembolism (VTE) as compared with patients from other races.

Updated on: December 22,2023 25

Study finds African Americans with cancer at higher risk for blood clots

byBoston University School of MedicineCredit: CC0 Public DomainAfrican-Americans are at higher risk for cancer-associated venous thromboembolism (VTE) as compared with patients from other races.

Updated on:December 22,2023 25

Optimizing Lung Cancer Treatment: The Role of CPT1A in Ferroptosis and Immunotherapy Enhancement

Updated on: June 15,2024 0

Optimizing Lung Cancer Treatment: The Role of CPT1A in Ferroptosis and Immunotherapy Enhancement

Updated on:June 15,2024 0

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W

Updated on: December 19,2023 23

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W

Updated on:December 19,2023 23

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer

Updated on: December 18,2023 15

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer

Updated on:December 18,2023 15

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on: October 17,2023 290

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on:October 17,2023 290

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023 10

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023 10

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on: December 17,2023 6

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on:December 17,2023 6

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on: December 19,2023 10

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on:December 19,2023 10